{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    15,
    16,
    17
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_4",
        "affectedSection": "Section 3.1.2 - Definitions of Terms",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Revised stable remission criteria to allow for a single excursion or missing assessment at specific weeks."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_4",
        "affectedSection": "Section 6.1.2.3 - Intranasal Treatment Session Frequency",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed the eligibility restriction regarding missed MADRS assessments during the first 8 weeks of the optimization phase."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_4",
        "affectedSection": "Section 11.7 - Interim Analysis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed the provision to stop the study for futility based on interim analysis results."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_3",
        "affectedSection": "Section 4.1.1 - Inclusion Criteria",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Revised antidepressant treatment requirements at study entry and non-response definitions to improve recruitment."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_4",
        "reasonText": "To enhance the number of clinically valid subjects proceeding to the Maintenance phase as stable remitters.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_4",
        "reasonText": "Potential outcome of placebo arm being as good as treatment arm may inform long-term use rather than indicating futility.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_4",
        "reasonText": "Clonidine is considered a safe and effective treatment option for blood pressure elevation.",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_3",
        "reasonText": "Based on feedback received from Investigators to improve recruitment.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.1.2",
        "beforeText": "MADRS total score ≤12 for the last 4 weeks of the optimization phase",
        "afterText": "MADRS total score ≤12 for at least 3 of the last 4 weeks of the optimization phase, but one excursion of a MADRS total score >12 or one missing MADRS assessment is permitted at Optimization week 13 or 14 only. The MADRS total score at weeks 15 and 16 must be ≤12.",
        "summary": "Modified stable remission definition to allow for limited excursions."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_4",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.2.3",
        "beforeText": "If ≥3 MADRS assessments are missed during the first 8 weeks of the optimization phase (Week 5 to Week 12), the subject can complete the optimization phase but is not eligible to participate in the maintenance phase.",
        "afterText": "None",
        "summary": "Removed restriction on missed MADRS assessments for maintenance phase eligibility."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.1",
        "beforeText": "On Days 18, 22, and 25, the dose must remain stable (unchanged).",
        "afterText": "On Days 18, 22, and 25, a dose reduction from 84 mg to 56 mg is permitted if required for tolerability; no dose increase is permitted.",
        "summary": "Permitted dose reductions for tolerability on specific induction days."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.2.1",
        "beforeText": "Evidence of 2nd and 3rd degree AV block, or 1st degree AV block with PR interval >200 msec",
        "afterText": "Evidence of 2nd and 3rd degree AV block",
        "summary": "Deleted exclusion for 1st degree AV block as esketamine showed no impact on PR interval."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 4
    }
  }
}